Prenatal and new-born genetic testing Market Industry Trends:
Prenatal and New-born Genetic Testing Market size was valued at over USD 4.7 billion in 2020 and is expected to grow at a CAGR of more than 11.8% between 2021 and 2028.
The main factor fueling the growth of the prenatal and new-born genetic testing market is the increasing prevalence of genetic disorders in newborns, including Edward syndrome, Down syndrome, Patau syndrome, and others. The market is expanding as a result of rising demand for screening for genetic abnormalities in the prenatal and newborn population. Additionally, significant technological advancements have been made as a result of significant investment in research activities and extensive genomics and proteomics research.
Prenatal genetic testing is the term used to describe tests performed during pregnancy to identify any potential genetic disorders or birth defects in the foetus. It is done to look for genetic disorders like Down’s syndrome, Tay-Sachs disease, cystic fibrosis, and sickle cell anaemia, among others. In order to screen for genetically inherited diseases or congenital anomalies like phenylketonuria (PKU), muscular spinal atrophy, critical congenital heart disease, hearing loss, and others, newborn genetic testing is conducted after a baby is born. Genetic testing during pregnancy and in the newborn is important for determining different options that can improve the baby’s health outlook. Prenatal and newborn screening improves patient outcomes and aids in the reduction of infant mortality.
However, a number of moral issues surrounding prenatal and newborn testing could stymie market growth. The development of clinical services and the implementation of public policies relating to access and funding are both constrained by the complex ethical issues raised by prenatal and new-born genetic testing. There are a number of issues with the use of screening in selective abortion. The adoption of genetic testing may be hindered by the rising incidence of false results in prenatal and newborn testing. For instance, during prenatal testing for Down syndrome, about 5% of women receive false-positive results.
Prenatal genetic screening will see increased technological developments, which will boost market revenue.
The prenatal and new-born genetic testing market’s screening sector is anticipated to develop at a 11.4% CAGR through 2027, driven by technical advancements, a surge in the usage of prenatal screening, and rising public awareness of birth abnormalities. Prenatal and postpartum screening tests are used to identify hereditary and congenital birth abnormalities. The risk of having a child with chromosomal disorders rises with age and is increased by pregnancy after the age of 35. The demand for acceptance of screening genetic tests will grow as the number of geriatric pregnancies rises. The size of the genetic screening test market would be further influenced by technological developments in non-invasive prenatal testing (NIPT), for example.
Request Access Full Report is Available:@ https://www.zionmarketresearch.com/report/prenatal-and-new-born-genetic-testing-market
Prenatal and new-born genetic testing Market COVID-19:
The COVID-19 pandemic has had no effect on the market for prenatal and newborn genetic testing. The coronavirus outbreak has killed a substantial number of people and affected millions of people worldwide. Lockdowns were implemented, and emergencies had been proclaimed in the majority of the countries to stop the spread of SARS-CoV-2. The supply chain was skewed and the flow of raw materials was curtailed as a result of the closure of significant economic sectors, which restrained the growth of the industry even more.
Patients who chose to get prenatal and newborn genetic testing subsequently had fewer in-person visits. A study conducted at the Cleveland Clinic Healthcare System found that the COVID-19 pandemic was to blame for a fall in prenatal and newborn genetic testing in the early 2020s. In order to limit visits to the overcrowded healthcare facilities, a sizeable fraction of study participants delayed the testing procedure. The practise of prenatal and newborn genetic testing would be further restricted by increased COVID-19 infection risk in expectant mothers. However, the industry would benefit from support provided by numerous public groups to continue the genetic testing of expectant mothers and newborns.
Major market players’ strategies will speed up industry expansion.
Ariosa Diagnostics (Roche), Berry Genomics, BGI, Biorad, Illumina, Laboratory Corporation of America, Natera, Qiagen, Sequenom, Trivitron Healthcare, and Verinata Health are a few of the leading businesses in the prenatal and new-born genetic testing sector. These significant actors place a strong emphasis on strategic efforts such as partnerships, purchases, the introduction of new products, and commercialization for market expansion. Additionally, successful businesses make significant investments in R&D that allow them to launch novel goods and generate the most possible income.
Request a Sample Copy of the Research Report:@ https://www.zionmarketresearch.com/sample/prenatal-and-new-born-genetic-testing-market
Prenatal and new-born genetic testing Market, By Technology
- Non-invasive (NIPT)
- Chorionic Villus Sampling (CVS)
- Maternal Serum Screening (MSS)
Prenatal and new-born genetic testing Market, By Disease
- Down’s Syndrome
- Cystic Fibrosis
- Sickle Cell Anaemia
Prenatal and new-born genetic testing Market, By End-use
- Maternity and Specialty Clinics
- Diagnostic Centers
Prenatal and new-born genetic testing Market By Region
- North America
- The U.S.
- The UK
- Rest of Europe
- Asia Pacific
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- South Africa
- Rest of the Middle East & Africa